This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Tenet Healthcare (THC) to Divest Hospitals for $1.1 Billion
by Zacks Equity Research
Tenet Healthcare (THC) to sell five hospitals to Steward Health Care System, LC for a deal value of $1.1 billion.
Tenet Healthcare (THC) Soars 69% YTD: More Room to Run?
by Zacks Equity Research
Banking high on a solid guidance and strategic measures, Tenet Healthcare (THC) holds enough potential to reap benefits for investors.
Community Health (CYH) Soars 111% YTD: More Room to Run?
by Zacks Equity Research
Community Health's (CYH) strategic initiatives are likely to boost its revenues, which in turn, might perk up its share price.
MEDNAX's (MD) Q1 Earnings Surpass Estimates, Decline Y/Y
by Zacks Equity Research
MEDNAX's (MD) Q1 results reflect lower costs. However, the same is partly offset by softer revenues.
Mednax (MD) Q1 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Mednax (MD) delivered earnings and revenue surprises of 60.00% and 2.36%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Healthcare Stock Q1 Earnings Due on May 7: ELAN, MD, MODV
by Sapna Bagaria
Varied companies across the vast healthcare space might have been affected differently by the COVID crisis during the first quarter.
Earnings Preview: Mednax (MD) Q1 Earnings Expected to Decline
by Zacks Equity Research
Mednax (MD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here's Why You Should Retain Mednax (MD) in Your Portfolio
by Zacks Equity Research
Riding high on strategic initiatives and telehealth medicine, MEDNAX (MD) holds potential to reap benefits for investors.
Mednax (MD) Up 31.6% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Mednax (MD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Mednax (MD) Ties Up With NightLight to Offer Better Pediatric Care
by Zacks Equity Research
Mednax (MD) collaborates with NighLight with an aim to offer enhanced pediatric care in Texas.
Tenet Healthcare (THC) Hits 52 Week High: Will the Rally Stay?
by Zacks Equity Research
Tenet Healthcare's (THC) shares display an upsurge as investors get optimistic about its latest strategic initiatives and cost-curbing measures.
Why Should You Add Community Health (CYH) to Your Portfolio?
by Zacks Equity Research
Riding high on telehealth services and cost-cutting measures, Community Health (CYH) holds potential to reap benefits for investors.
MEDNAX's (MD) Q4 Earnings Fall Shy of Estimates, Tumble Y/Y
by Zacks Equity Research
MEDNAX's (MD) fourth-quarter results reflect muted revenues caused by the COVID-19 pandemic.
Mednax (MD) Q4 Earnings and Revenues Miss Estimates
by Zacks Equity Research
Mednax (MD) delivered earnings and revenue surprises of -19.35% and -8.64%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Here's Why You Should Hold MEDNAX (MD) in Your Portfolio Now
by Zacks Equity Research
Riding high on its strategic efforts and cost-cutting measures, MEDNAX (MD) holds enough potential to reap benefits for investors.
Tenet Healthcare (THC) Up 126.9% in 6 Months: More Room for Rally?
by Zacks Equity Research
Tenet Healthcare's (THC) strategic measures and cost-controlling efforts are expected to drive its margins, which in turn, might inflate its share price.
Mednax (MD) Up 60.5% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Mednax (MD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
MEDNAX's (MD) Q3 Earnings Meet Estimates, Revenues Miss
by Zacks Equity Research
MEDNAX's (MD) third-quarter results reflect muted revenues and high costs, partly offset by lower interest expense.
Mednax (MD) Lags Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Mednax (MD) delivered earnings and revenue surprises of -7.50% and -13.87%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Mednax (MD) Q3 Earnings Expected to Decline
by Zacks Equity Research
Mednax (MD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Why Should You Retain MEDNAX (MD) in Your Portfolio Now?
by Zacks Equity Research
Riding on restructuring as well as cost-cutting initiatives, MEDNAX (MD) holds potential to reap benefits for investors.
MEDNAX Divests Radiology Business to Focus on Core Operations
by Zacks Equity Research
MEDNAX (MD) reaches an agreement with Radiology Partners to sell its MEDNAX Radiology Solutions, which will lower its debt load and restructure its business.
MEDNAX (MD) Catches Eye: Stock Jumps 5.4%
by Zacks Equity Research
MEDNAX (MD) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.
Why Should You Hold on to Tenet Healthcare (THC) Stock?
by Zacks Equity Research
Riding high on divestitures and cost-reduction, Tenet Healthcare (THC) holds enough potential to reap benefits for yield-seeking investors.
Why Is Mednax (MD) Down 5.3% Since Last Earnings Report?
by Zacks Equity Research
Mednax (MD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.